An investigation for investors in NYSE:ARA was announced over potential breaches of fiduciary duties by certain officers and directors at American Renal Associates Holdings.
Investors who purchased shares of American Renal Associates Holdings Inc (NYSE:ARA) and currently hold any of those NYSE:ARA shares have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain American Renal Associates Holdings directors breached their fiduciary duties and caused damage to the company and its shareholders.
American Renal Associates Holdings Inc reported that its annual Total Revenue rose from $495.93 million in 2013 to $652.98 million in 2015 and that its Net Loss of $20.45 million in 2103 turned into a Net Income of $18.84 million in 2015.
American Renal Associates Holdings Inc went public in April 2016. Shares of American Renal Associates Holdings Inc (NYSE:ARA) grew from $27.06 per share in May 2016 to as high as $29.21 per share in June 2016. On July 1, 2016 it was reported that UnitedHealth Group Inc. sued American Renal Associates Holdings Inc. accusing it of fraud.
On July 11, 2016, NYSE:ARA shares closed at $27.38 per share.
Those who purchased NYSE:ARA shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego